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Abstract
Purpose of review Most hypertension devices have been designed to interrupt or modify the sympathetic nervous system, which
seems to be unbalanced in hypertension. Carotid baroreceptors play a pivotal role in maintaining adrenergic balance via a direct
feedback interface and would be an exceptional target for intervention. The purpose of this review is to define the role of the
baroreceptor in hypertension, to examine device-based therapies targeting the baroreflex and to explore future promises of
endovascular baroreflex amplification (EBA).
Recent findings In the last two decades, two therapeutic strategies targeting the carotid baroreceptor have evolved: baroreflex
activation therapy (BAT) and EBA. Both therapies enhance baroreceptor activity, either directly by electrical stimulation or
indirectly by changing the geometric shape of the carotid sinus and increasing pulsatile wall strain.
Summary By showing a significant, sympathetic inhibition-mediated effect on blood pressure, BAT has laid the foundation for
baroreflex-targeting therapies for resistant hypertension. EBA is a less invasive therapy with promising first-in-man study results.
Ongoing randomized sham-controlled trials are needed to better understand efficacy, durability, and long-term safety and define
phenotypes that may most benefit from this treatment.
Keywords Resistant hypertension . Sympathetic activity . Baroreceptor . Device-based antihypertensive therapy . Baroreflex
activation therapy . Endovascular baroreflex amplification

Introduction
Approximately 10–15% of all treated hypertensive patients
have resistant hypertension. Resistant hypertension is defined
as blood pressure (BP) that remains above target despite adequate treatment with three or more antihypertensive medications, including a diuretic, or treatment with four or more
antihypertensive medications irrespective of BP status [1•].
This article is part of the Topical Collection on Hypertension and the
Kidney
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Patients with resistant hypertension are at increased risk of
target organ damage and cardiovascular events [2]. Although
contemporary hypertension best medical therapy is often effective, some patients do not respond or cannot tolerate the
prescribed antihypertensive medication regimen. This unmet
need led to a growing interest in device-based therapies as an
alternative or adjuvant to drugs. An exceptional target for
these device-based therapies is the arterial baroreflex, which
plays a central role in the development as well as propagation
of the hypertensive continuum [3•].
Stimulation of the carotid baroreceptor leads to increased
baroreceptor firing and reduced sympathetic outflow, resulting
in a decrease in BP. Baroreflex activation therapy (BAT), in
which a surgically implanted electrical stimulator activates the
baroreceptor on the outer carotid sinus wall, is one of the
device-based therapies that exploits this feedback loop.
Although some efficacy endpoints were positive in a randomized, sham-controlled trial [4••], there are considerable disadvantages: the procedure is invasive, costly, has numerous adverse effects [5], and the battery needs replacement every 3 to
5 years. Endovascular baroreflex amplification (EBA), in
which an endovascular device implanted inside the carotid
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sinus modulates baroreceptor activity, is a less invasive therapy targeting the baroreflex. The first safety and efficacy results
of EBA are promising [6••]. This review will focus on baroreceptor stimulation to lower BP in patients with resistant
hypertension. First, we will outline the problem of resistant
hypertension and provide a clinical framework for the application of device-based therapies targeting the carotid baroreceptor. Thereafter, we will discuss the role of the baroreceptor
in hypertension and elaborate on the two therapies targeting
the baroreflex: BAT and EBA.

Curr Hypertens Rep (2018) 20: 46

which still can be extrapolated to tens or hundreds of million
patients worldwide.
Resistant hypertension is characterized by increased sympathetic drive [3•]. Studies quantifying sympathetic activity
by measuring muscle sympathetic nerve activity (SNA) at
the peroneal nerve have shown an increase in SNA in prehypertensive stages [21]. SNA progressively increases from
mild to severe hypertension [22] and is even more pronounced
in patients with resistant hypertension [23•]. Increased SNA is
associated with target organ damage and an increased risk of
cardiovascular events [3•]. Therefore, the sympathetic nervous system has become one of the most important targets
for device-based therapies in the last decade.

Resistant Hypertension and Sympathetic
Nervous System
Baroreflex Physiology
The term resistant hypertension was initially introduced to define a group of high risk patients in which screening for secondary causes of hypertension as well as intensified treatment
should be considered [1•]. Resistant hypertension is defined as
BP that remains above target despite treatment with three or
more antihypertensive medications of different classes, including a diuretic, or treatment with four or more antihypertensive
medications of different classes irrespective of BP status [7].
Prevalence of resistant hypertension ranges from 8.4 to 17.4%
in patients medically treated for hypertension [8–17] and from
8.9 to 12.8% [14–17] in all hypertensive patients. The hypertension device trials have led researchers to better define “resistant hypertension.” Yet, this disambiguation process has
been challenging. For example, there are patients with socalled pseudo-resistant hypertension: patients who appear to
be resistant to therapy due to white coat effect or nonadherence to medication. The prevalence of white coat effect
(ambulatory BP measurements being normal) among patients
with resistant hypertension is estimated at 35.7% [18]. Also, the
prevalence of non-adherence is surprisingly high in this population. Recent studies using therapeutic drug monitoring (in
urine or plasma) to assess non-adherence to antihypertensive
medication report percentages of 53 to 68% [19, 20].
It is important to identify pseudo-resistance early in the
clinical decision-making process. Cardiovascular risk in patients with true resistant hypertension is at least two times as
high compared to those with controlled ambulatory BP [2].
Therefore, classification identifies patients at higher risk and
justifies treatment intensification. Moreover, this classification
is crucial to distinguish the patients that may benefit from
expensive and potentially harmful device-based treatments
from those in which alternative strategies, i.e., improving
medication adherence, should be initiated. To date, the ideal
study estimating the prevalence of true resistant hypertension
has not yet been conducted. However, considering the aforementioned numbers of pseudo-resistance, prevalence of true
resistant hypertension will not be much higher than 5–10%,

As the baroreceptors are important modulators of SNA, they
are an exceptional target for antihypertensive therapy. Arterial
baroreceptors are mechanosensitive nerve fibers located in the
carotid sinus, close to the bifurcation, and in the aortic arch.
These nerve fibers are located in a specialized area in the
lateral wall of the carotid sinus, opposite the carotid body
(another neural structure involved in BP control). The carotid
sinus contains more collagen and less smooth muscle cells
than the innominate, making it more compliant and contributing to stretch-induced activation of the baroreceptors [24].
Baroreceptors react on stretch rather than pressure. This has
been demonstrated in an experimental model of a carotid sinus
imbedded in a non-distensible plaster in which baroreceptor
firing remained unaffected by increases in arterial pressure
[25]. Baroreceptor nerve fibers contain ion channels that are
sensitive to mechanical deformation [26•]. Increase in wall
strain causes influx of sodium and calcium ions through these
channels, depolarizing the nerve terminal and generating action potentials that travel along the afferent nerve [27]. The
frequency of firing depends on the magnitude of deformation
and the properties of the ion channels and ion pumps located
at the nerve terminal. Via the glossopharyngeal and vagus
nerves, these signals travel to the nucleus tractus solitarius
(NTS) in the caudal medulla. The NTS is the main regulatory
center of the BP that integrates multiple information from
different organ systems and the cerebral cortex. This central
role of the NTS in BP regulation has been demonstrated in rat
experiments. Blockage of neurotransmission in the NTS
strongly attenuated the baroreflex [28] and specific lesions
in the NTS eliminated baroreceptor responses completely
[29]. In the NTS, two signaling pathways arise: the parasympathetic and sympathetic pathway. Signals from the parasympathetic pathway travel via the nucleus ambiguous to the
heart, where parasympathetic drive is increased. The signals
from the sympathetic pathway travel via the caudal ventrolateral medulla, where the signal is conversed into an inhibitory
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signal, to the rostral ventrolateral medulla (RVLM) decreasing
sympathetic output [30]. The RVLM is critical for maintenance of vascular tone and is the primary output nucleus for
muscle SNA.
In hypertensive patients, the baroreceptor undergoes complex changes to compensate chronic high BP status.
Baroreceptors in hypertensive patients fire at higher pressures
compared to normotensives in order to prevent saturation of
the reflex and avoid extreme vasoconstriction and tachycardia
[3•]. Although the baroreflex control of heart rate (parasympathetic pathway) is impaired [22], the baroreflex control of
BP (sympathetic pathway) is unaffected in hypertension [31].
Therefore, the baroreceptors retain their ability to respond to
transient changes in BP. This means that there is a shift in
baroreflex activation to a higher set point, in other words,
the baroreceptors are reset. Although, the specific mechanisms
underlying resetting of the carotid baroreflex are yet unknown, it is likely to be multifactorial process including peripheral as well as central mechanisms [32, 33].
Considering the aforementioned mechanisms, modulating
the baroreflex to decrease sympathetic activity seems a promising strategy to lower BP. Two device-based therapies that
rely on this mechanism are BAT and EBA. BAT increases
baroreceptor firing rate by directly delivering electric pulses
to the baroreceptor nerve endings on the outer wall of the
carotid sinus. EBA relies on mechanically changing the geometric shape of the carotid sinus during cardiac systole, which
increases pulsatile strain. Pulsatility is crucial since static increases in BP reset the baroreceptor immediately, where pulsatile strain attenuates baroreceptor resetting [34]. This explains the difference in BP response to conventional carotid
stenting, where low BP returns to normal within a few days,
and implantation of the dynamic MobiusHD device, where
decrease in BP sustains.

Lessons Learned from Baroreflex
Amplification Therapy
Implantation of an electrical stimulator to activate the baroreceptor was already performed in humans in the 1950s [35].
Application of this technique in patients with severe hypertension [36, 37] or angina pectoris [38] showed a significant
decrease in BP and relief of angina. Despite these promising
results, the interest in electrical baroreceptor stimulation as a
treatment strategy for hypertension declined due to the introduction of more effective and better tolerated antihypertensive
drugs, and the technical problems associated with the first
electrical stimulators. It is only since the last decade that baroreceptor stimulation regained interest for treatment of patients
with resistant hypertension.
The Rheos system, an implantable electrical stimulator, has
been developed by CVRx and was first investigated in 11
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patients undergoing elective carotid endarterectomy [39].
Unilateral electric stimulation of the carotid sinus wall during
surgery decreased systolic BP from 144 ± 9 to 131 ± 9 mmHg.
The first permanent implantations in humans were performed
in a European multicenter feasibility study (the DEBuT-HT
study) that included patients with resistant hypertension (office BP ≥ 160 mmHg systolic or ≥ 90 mmHg diastolic despite
treatment with at least three antihypertensive medications, including a diuretic) between 2004 and 2007 [40•]. Firstgeneration Rheos stimulation electrodes were placed bilaterally on the outer wall of the carotid sinus and connected to an
impulse generator positioned inferior to the clavicle. BP decreased by 21/12 ± 4/2 mmHg at 3 months (n = 37) and 33/22
± 6/4 mmHg after 2 years (n = 17). The subsequent randomized double-blind Rheos Pivotal trial could not prove significant acute efficacy (proportion of patients that achieve at least
10 mmHg decrease in systolic BP at 6 months) and procedural
safety (serious procedure- or system-related adverse eventfree rate within 30 days of implantation) [4••]. However, the
study did show a significant difference in the proportion of
patients that reached systolic BP ≤ 140 mmHg: 42% in the
active treatment group and 23% in the placebo group.
Moreover, systolic BP decreased by 26 ± 30 mmHg in the
active treatment group versus 17 ± 29 mmHg in the placebo
group, at 6 months compared to pre-implantation.
Additionally, a 40% reduction of hypertensive events in the
active treatment group was observed. Yet, the substantial rate
of general surgical complications and nerve injury causing
transient or residual symptoms as localized numbness, dysphagia, or dysphonia led to the development of a secondgeneration device: the Barostim neo. The electrodes of the
Barostim neo are substantially smaller in size, and it requires
unilateral implantation only.
The Barostim neo has only been investigated in nonrandomized studies so far. The first studies showed a significant systolic office BP decrease of 26 ± 4 mmHg (n = 30),
comparable with the first-generation results [41•], and systolic
24-h ambulatory BP decrease from 148 ± 17 to 140 ±
23 mmHg (n = 44) [42] at 6 months. Forty-three percent
reached systolic office BP ≤ 140 mmHg [41•]. More importantly, considerably less system- or procedure-related events
occurred compared to the first-generation device [41•, 42].
Proof of mechanism studies with first- and secondgeneration devices have confirmed that depressor response
to BAT was mediated through sympathetic inhibition [5,
43••] and have shown that physiologic regulation of the baroreflex remained unaffected [43••]. The Barostim neo is currently being investigated in a randomized double-blind clinical trial: the Nordic BAT study [44].
The aforementioned clinical trials on BAT provide the evidence that baroreflex activation is an effective strategy to
lower BP in patients with resistant hypertension. However,
due to the current lack of results from randomized double-
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blind clinical trials, the side effects that occur with increased
energy delivery [5], the need for a surgical procedure, the high
costs, and the need for battery replacement every 3–5 years,
there has been a pursuit for alternative techniques to activate
the baroreflex and lower BP.

Endovascular Baroreflex Amplification
EBA relies on a passive activation of the baroreceptor by
intermittingly changing the geometric shape of the carotid
sinus which increases pulsatile wall stretch (Fig. 1a). The
MobiusHD is a self-expanding nitinol implant that promotes
this geometric shape change. The mechanism of action is not
intuitive: the outward radial forces of the longitudinal nitinol

Fig. 1 b–d Images are
reproduced by permission of
Vascular Dynamics, Inc. a Crosssectional view of the carotid sinus
in three different situations. In the
untreated vessel, the radius
increases pulsatile during the
systolic phase of the cardiac
cycle. The MobiusHD implant
changes the geometric shape of
the vessel during the systole and,
therefore, increases the effective
radius (Δr, in red). This results in
increased vessel wall strain while
preserving pulsatility. The
conventional carotid stent drives
the carotid sinus into a static
circular shape, blunting
baroreceptor function. b The selfexpendable nitinol MobiusHD
device (c) implanted in the
proximal internal carotid artery. d
The device is delivered by a
specially developed delivery
catheter, introduced over a
guidewire via the femoral artery. e
Reproduced from Peter DA,
Alemu Y, Xenos M. Fluid structure
interaction with contact surface
methodology for evaluation of
endovascular carotid implants for
drug-resistant hypertension
treatment. Journal of Biomedical
Engineering. 2012:134;041001–
6. DOI: 0.1115/1.4006339.
Computer simulation showing
circumferential and longitudinal
wall stretch variation in an
average carotid sinus after device
implantation, plotted for the plane
shown on the left
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struts are not active components of the device, rather the
carotid bulb components within the windows of the device.
In the systolic phase of the cardiac cycle, the arc of the carotid
in each window of the device projects a radius that is much
larger than the radius of the baseline carotid bulb without
geometric change. According to the strain equation, increased
wall strain or vessel stretch would be expected with each
systolic phase. In the diastolic phase of the cardiac cycle,
quadrants within the device windows return to the baseline
exaggerated arc. Therefore, the end result of the MobiusHD is
increased carotid sinus pulsatile stretch. The implant is available in three sizes: 5.00–7.00 mm, 6.25–9.00 mm, and 8.00–
11.75 mm and is placed into the internal carotid artery by a
specially developed delivery catheter introduced over a
guidewire via the femoral artery (Fig. 1b–d).

Curr Hypertens Rep (2018) 20: 46

Animal Studies
The pre-clinical evaluation included several animal models to
study the effect of MobiusHD implantation on hemodynamics
and vessel anatomy. In a canine model, carotid baroreceptor
firing rate was measured after implantation of the MobiusHD
and compared to implantation of conventional self-expanding
carotid stent [6••]. The carotid stent caused a stair step increase
of carotid baroreceptor nerve activity that was decoupled with
BP. In contrast, the MobiusHD not only increased immediate
baroreceptor firing rate to a greater extent than the conventional carotid stent but, more importantly, showed a progressive linear increase in firing as the animal’s BP was increased
(Supplementary Fig. 1A). In addition, these experiments
showed that MobiusHD implantation was followed by an immediate drop in BP (Supplementary Fig. 1B). In order to optimize design and ensure radial force could be programmed to
reduce vessel injury or device migration through the vessel
wall, several ovine carotid survival studies were performed
to inform design metrics (data unpublished). Since few animals have carotid baroreceptors and an ideal surrogate for the
human carotid artery is lacking, information of the effect of
MobiusHD implantation on carotid biomechanics and hemodynamics largely comes from computer simulation studies.

Computer Simulation Studies
The effect of MobiusHD implantation on the carotid wall and
vessel hemodynamics was studied by fluid-structure interaction combined with contact surface methodology. This technology allows for a three-way coupled dynamic interaction
simulation of the endovascular device, carotid sinus, and fluid
flow [45••]. Simulations were performed in two carotid
models: the first representing an average carotid artery in
terms of geometry and dimensions and the second
representing the clinical worst-case scenario of a carotid bifurcation, devoid of a typical sinus, much smaller in dimensions,
and having the internal and external carotid arteries (ICA and
ECA) aligned almost parallel to each other (Supplementary
Fig. 2A). The simulations showed an increase in carotid wall
stretch and strain after MobiusHD deployment, affecting hemodynamics only in extreme situations. In the average model
device, placement resulted in increased circumferential and
longitudinal wall stretch of 2.5 and 7.5%, respectively. Von
Mises wall stress in the ICA increased from 198 to 305 kPa
(Supplementary Fig. 2B). The peak stress at the level of the
bifurcation and the peak flow velocity in ICA and ECA did
not change. In the diminutive model, circumferential and longitudinal wall stretch both increased with 6%. Von Mises wall
stress in the ICA increased from 60 to 90 kPa. Device deployment caused a reduction of the ECA inflow area, increasing
the velocities and peak stress at the level of the bifurcation:
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peak stress increased from 211 to 622 kPa. Since increased
stretch and stress increases baroreceptor firing rate [46•], these
elevations are presumed to activate the baroreflex and reduce
BP.
This simulation study additionally showed that pulsatility
of the average carotid wall, although moderately attenuated,
was maintained [45••] (Fig. 1e). The authors reason that the
observed attenuated pulsatility is exaggerated as a result of
prespecified characteristics of the device material: modeling
was performed with stainless steel properties, being less elastic and stiffer than the nitinol the MobiusHD is made of.
Therefore, these studies predict that the MobiusHD implantation preserves pulsatility in the carotid vessel.

Results from the First-in-Man Study
Two parallel proof-of-principle studies investigated the safety
and efficacy of EBA in patients with resistant hypertension:
controlling and lowering blood pressure with the MobiusHD,
first in man, USA and Europe (CALM-FIM_US and CALMFIM_EUR). The first MobiusHD implantation in human was
performed in 2013, Atlanta, USA. The CALM-FIM_EUR
study enrolled the last patient in February 2017, and the results
of this study were published in September 2017 (6••). The
CALM_FIM_EUR study included 30 patients in six
European centers: five in The Netherlands and one in
Germany. Patients were eligible if they were 18–80 years of
age; diagnosed with primary resistant hypertension; taking a
stable regimen for at least 30 days with maximally tolerated
doses of at least three antihypertensive drugs from different
classes (one of them being a diuretic); and having a mean
systolic office BP of at least 160 mmHg, mean 24-h ambulatory
BP of at least 130 mmHg systolic, and at least 80 mmHg diastolic. The main exclusion criteria were hypertension secondary to an identifiable and treatable cause other than sleep apnea;
any plaque or ulceration in the carotid artery or aortic arch;
inadequate diameter or anatomy of the carotid vessels; history
of orthostatic hypotension or syncope; atrial fibrillation; history
of myocardial infarction in the past 3 months; history of cerebral vascular accident in the past 12 months; and severe renal,
cardiac, or pulmonary disease. MobiusHD implantation was
performed by interventionists that had at least performed 100
carotid stent implants before. Patients were treated with dual
antiplatelet therapy aspirin, and clopidogrel (or equivalent), administered 3 days before up to 3 months after the procedure.
Aspirin was continued indefinitely.
Patients were on average 52 years old, 15 (50%) were female, 8 (27%) had failed renal denervation, mean office BP
was 184/109 mmHg (SD 18/14), mean 24-h ambulatory BP
166/100 mmHg (SD 177/14), and mean number of antihypertensive medications 4.4 (SD 1.4). The primary endpoint was
the incidence of serious adverse events (SAEs) and
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unanticipated device effects (UADEs) at 6 months. In the first
6 months, two patients had to be treated because of severe
hypotension, two because of worsening of hypertension (one
case in which both hypotension and hypertension occurred),
and one because of dislodgement of the femoral closure device.
After thromboendarterectomy, this patient developed a wound
infection, which was treated by wound irrigation and antibiotics. No UADEs occurred. Most common adverse events were
dizziness, musculoskeletal pain, hypotension, and groin hematoma. Not unimportantly, two patients in one center had a transient ischemic attack; fortunately, their symptoms resolved.
Mean office BP (average of two readings after 5 min
rest, measured seated with an automated oscillometric device) decreased by 24/11 mmHg (95%CI 12–35/4–18) at
3 months and 24/12 mmHg (95%CI 13–34/6–18) at
6 months. Mean 24-h ambulatory BP decreased by 15/
8 mmHg (95% CI 7–23/3–13) at 3 months and 21/
12 mmHg (14–29/7–16) at 6 months. This decrease was
seen on top of reduction in the number of antihypertensive
medication by 0.5 (IQR 1.3–0.0). Unfortunately, only selfreported use of medication was assessed.
Although the sample size is small and the results of this
proof-of-principal study can be highly affected by different
types of bias, including regression to the mean, Hawthorneeffect, placebo effect, and observer bias, the observed decrease in BP is promising. More information on adverse effects in a larger group of patients is needed before we can
reasonably state that the treatment is safe. Moreover, we need
to wait for the results of the randomized, sham-controlled
clinical trials to prove its efficacy.

Ongoing Clinical Trials
The CALM-START study (controlling and lowering blood
pressure with the MobiusHD—studying effects in a randomized trial) is currently enrolling patients with primary resistant
hypertension in planned six centers in the Netherlands and
four in Germany. In this randomized sham-controlled trial,
patients aged 18–70 on a stable regimen of three to four antihypertensive medications and mean 24-h ambulatory systolic
BP of 135–170 mmHg are randomized to MobiusHD implantation or sham. The primary endpoint is change in mean 24-h
ambulatory systolic BP at 3 months, measured after antihypertensive medication washout. The CALM-2 study (controlling and lowering blood pressure with the MobiusHD) is a
second randomized, sham-controlled multicenter trial studying the effect of EBA on BP and is planned to start recruiting
patients in spring 2018. In this study, patients with resistant
hypertension and mean 24-h ambulatory systolic BP of 145–
200 mmHg on a confirmed stable regimen of three to five
maximally tolerated antihypertensive medications (containing
at least an angiotensin-converting enzyme inhibitor or
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angiotensin II receptor blocker, a calcium channel blocker,
and a diuretic) will be randomized. The primary endpoint is
change in mean 24-h ambulatory systolic BP, obtained after
observed drug intake at 6 months. These randomized trials
will also provide us with more elaborate information on the
efficacy and safety profile of EBA.
In addition, we are currently conducting a proof-ofmechanism study to determine the effect of EBA on SNA
and baroreceptor sensitivity, in a sub-study of the CALMDIEM study (controlling and lowering blood pressure with
the MobiusHD—defining efficacy markers). In this study, patients with therapy-resistant hypertension who are eligible for
MobiusHD implantation undergo microneurography, cardiovascular measurements, and functional magnetic resonance
imaging at baseline and 3 months, after washout of antihypertensive medications that influence sympathetic activity.
Hopefully, this study will give us insight in the physiological
mechanisms by which EBA reduces BP and may help us to
identify which patients benefit most from treatment.

Possible Benefits beyond Blood Pressure
In addition to the effect on BP and the associated decrease
of target organ damage, reduced sympathetic activity may
have direct beneficial effects on cardiac function, renal
function, and insulin sensitivity. From prospective studies
in patients with primary hypertension [47] and patients with
heart failure [48, 49], we know that sympathetic overactivity is associated with left ventricular hypertrophy, cardiac arrhythmias, and progressive heart failure, independent
of BP. Therefore, baroreceptor stimulation may also be beneficial for patients with heart failure. A non-randomized
study investigated the effect of BAT in patients with New
York Heart Association functional class III heart failure and
showed favorable effects on subjective (quality of life) and
objective (left ventricular ejection fraction and BNP) heart
failure-related outcomes [50]. A beneficial effect of sympathetic inhibition was also observed in one of our study
participants, who exhibited a sharp reduction of premature
ventricular complexes, 3 months after EBA.
Furthermore, sympathetic inhibition may counteract the
negative effects of sympathetic outflow to the kidneys: renin
release, sodium reabsorption, and renal vasculature changes
[51] (including smooth muscle cell proliferation and vasoconstriction) leading to proteinuria and glomerulosclerosis [52].
Sympathetic inhibition may slow down progression of renal
disease or improve renal function. In a non-randomized,
single-center study, 23 patients with chronic kidney disease
stage 3 or higher treated with the Barostim neo showed reduced proteinuria compared to patients who did not receive
BAT [53]. However, no difference in estimated glomerular
filtration rate was observed.
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Finally, EBA may play a role in regulating glucose
metabolism. From earlier studies, we know that impaired
glucose metabolism and hypertension often coexist. Most
likely, hyperinsulinemia is preceded by increased sympathetic activity. The evidence comes from a prospective
cohort study in Japan, which followed 662 normotensive
and 188 borderline hypertensive age- and body mass
index-matched patients for 10 years [54]. One of the explanations for the occurrence of hyperinsulinemia is that
sympathetic activation leads to vasoconstriction, which
lowers skeletal muscle blood flow and reduces glucose
delivery to skeletal muscles [55] [56]. The effect of baroreflex stimulation on insulin sensitivity was investigated
in a randomized, double-blind, cross-over trial in BP responders treated with BAT. Acute change of chronic baroreceptor stimulation did not significantly change muscular
glucose delivery and insulin sensitivity [57]. Whether
EBA improves cardiac function, renal function, and insulin sensitivity remains to be determined.

Conclusions
From a pathophysiological point of view, the carotid
baroreceptor is an exceptional target to treat hypertension. This has been confirmed in the clinical trials evaluating BAT, showing a significant, sympathetic
inhibition-mediated decrease in BP. Therefore, BAT has
laid the foundation for baroreflex-targeting devices as an
additive treatment for true resistant hypertension. As amplification of the baroreflex by a passive endovascular
implant is less invasive, probably less costly, and does
not need battery replacement every 3–5 years, EBA may
be a good alternative. Although the results of the first-inman study are promising, efficacy, durability, and safety
results from randomized sham-controlled clinical trials
are needed before it can be implemented as a standard
medical therapy. Furthermore, future research should address which patients benefit most from EBA and should
examine the additional effects of sympathetic inhibition
beyond lowering BP.
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